What question did this study set out to answer?

The study investigates the effects of resveratrol on atherosclerosis-related processes in vitro and in vivo using LDL receptor-deficient mice.

January 10, 2026Antioxidants0 citationsOpen Access

Resveratrol Mediates Anti-Atherogenic Actions In Vitro and in LDL Receptor-Deficient Mice Fed a High-Fat Diet via Antioxidant, Anti-Inflammatory and Plaque-Stabilising Activities

AAAlaa AlahmadiUniversity of Jeddah RAReem AlotibiUniversity of Jeddah YCYee-Hung Chan

Key Result

Resveratrol improved the plasma lipid profile and reduced plaque inflammation in LDL receptor-deficient mice, enhancing plaque stability through increased smooth muscle and collagen levels.

Key Points

The study investigates the effects of resveratrol on atherosclerosis-related processes in vitro and in vivo using LDL receptor-deficient mice.
Examined the impact of resveratrol on monocytes, macrophages, endothelial cells, and smooth muscle cells in vitro.
Utilized LDL receptor-deficient mice fed a high-fat diet for in vivo analysis.
Analyzed changes in plasma lipid profiles and immune cell demographics.
Performed RNA-sequencing on thoracic aorta to identify genes and pathways affected by resveratrol.
Resveratrol improved plasma lipid profiles and reduced inflammation in plaques.
Decreased macrophage and T cell content led to enhanced plaque stability.
In vitro, resveratrol inhibited monocyte migration and reactive oxygen species production.
Identified key genes and pathways involved in the antioxidant and anti-inflammatory effects of resveratrol.

Structured PICO

Does resveratrol mediate anti-atherogenic actions in vitro and in LDL receptor-deficient mice fed a high-fat diet?

Population

In vitro models (monocytes, macrophages, endothelial cells, and smooth muscle cells) and in vivo LDL receptor-deficient mice fed a high-fat diet

Intervention

Resveratrol (RSV)

Outcome

Impact on key atherosclerosis-associated processes including plasma lipid profile, plaque inflammation, and plaque stabilitysurrogate

Resveratrol demonstrates anti-atherogenic properties through antioxidant, anti-inflammatory, and plaque-stabilizing mechanisms in preclinical models, supporting its potential as a nutraceutical therapy for atherosclerotic cardiovascular disease.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

Current pharmacotherapies against atherosclerotic cardiovascular disease are associated with considerable residual risk, together with various adverse side effects. Nutraceuticals, such as resveratrol (RSV), with excellent safety profile, represent promising alternatives and potential treatment. However, the full spectrum of anti-atherogenic actions regulated by RSV and the underlying molecular mechanisms remain poorly understood. The objective of this study therefore was to investigate the impact of RSV on key atherosclerosis-associated processes in monocytes, macrophages, endothelial cells, and smooth muscle cells in vitro, as well as in LDL receptor-deficient mice fed a high-fat diet in vivo. RSV produced beneficial changes in the plasma lipid profile and peripheral blood lymphoid cells in vivo. RSV also attenuated plaque inflammation by decreasing macrophage and T cell content and enhanced markers of plaque stability, with increased levels of smooth muscle cells and collagen content. In vitro, RSV inhibited chemokine-driven monocyte migration, inflammasome activation, matrix metalloproteinase activity, pro-inflammatory gene expression, reactive oxygen species production, and smooth muscle cell invasion. RNA-sequencing of the thoracic aorta revealed key genes and pathways mediating the antioxidant, anti-inflammatory and plaque-stabilising activities of RSV. These studies provide novel mechanistic insights on the anti-atherogenic actions of RSV and support further evaluation in human clinical trials.

Ask AI

Helpful

Bookmark

View Full Paper